Alvimopan: A peripherally selective opioid mu receptor antagonist

Formulary

Volumn 40, Issue 6, 2005, Pages 176-183

  Udeh, Elizabeth ^a,b   Goldman, Monica ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVIMOPAN; MU OPIATE RECEPTOR ANTAGONIST; OPIATE; OPIATE RECEPTOR;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ANALGESIA; CLINICAL TRIAL; COST; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; ILEUS; NAUSEA; NONHUMAN; OLIGURIA; PAIN; PRURITUS; REVIEW; TACHYCARDIA; VOMITING;

EID: 21744445222     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction. Drugs. 2003;63(7):649-671.
2. Schmidt WK. Alvimopan (ADL-8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182(Suppl to November 2001):27S-38S.
3. Adolor Corporation news releases. Adolor completes submission of NDA for Entereg (alvimopan) in postoperative ileus. Available at: http://phx. corporate-ir.net/phoenix.zhtml?c=120919&p=irolnewsArticle&t= Regular&id=585562&. Accessed May 11, 2005.
4. Zimmerman DM, Gidda JS, Cantrell BE, et al. LY246736 Dihydrate. Mu opioid receptor antagonist. Drugs Future. 1994;19:1078-1083.
5. Zimmerman DM, Gidda JS, Cantrell BE, et al. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994;37:2262-2265.
6. Liu SS, Hodgeson PS, Carpenter RL, Fricke JR. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001;69(1):66-71.
7. Taguchi A, Sharma W, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001;345(13):935-940.
8. Delaney C, Weese J, Hyman N. Prospective, randomized, double-blind, multicenter, placebo-controlled study of alvimopan, a novel peripherally-acting mu opioid antagonist for postoperative ileus after major abdominal surgery [abstract]. Dis Colon Rectum. 2004;47:589.
9. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel peripherally acting mu opioid antagonist; results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240(4):728-735.
10. Liberto JG, Herschler JA, Jaffe JH, et al. Effects of ADL 8-2698, a peripherally restricted mu opioid antagonist, on gut mobility in methadone and LAAM dependent patients with opioid-induced constipation: a dose ranging study [abstract]. Drug Alcohol Depend. 2001;63:591.
11. Paulson DM, Kennedy DT, Donovick RA, et al. An oral, peripherally acting, mu opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction for the treatment of opioid induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain. 2004;6(3):184-192.